The FDA has issued updated information on atypical fractures of the femur associated with the use of bisphosphonates to treat osteoporosis. These drugs include Fosamax® (alendronate sodium), Actonel® (risedronate sodium), Boniva® (ibandronate sodium), Atelvia™ (risedronate sodium), Reclast® (zoledronic acid), and their generic equivalents.
Click here for more information.
WASHINGTON, DC (January 20, 2011) — The National Osteoporosis Foundation (NOF) recommends a comprehensive approach to the diagnosis and management of osteoporosis. A detailed history and physical examination together with Bone Mineral Density (BMD) assessment and, where appropriate, the WHO 10-year estimated fracture probability are utilized to establish the individual patient’s fracture risk.
Because health reform legislation, the Affordable Care Act, was signed into law on March 23, 2010, health care coverage is more available this year. For most people with or at risk for osteoporosis, the legislation also should improve their health care and make it more affordable.*
Thanks to advocates like you, NOF made substantial progress in advancing osteoporosis and bone health on the national health agenda. As we prepare for 2011 and the new Congress, we would like to reflect on the achievements of 2010.
WASHINGTON, DC (November 30, 2010) — The National Osteoporosis Foundation (NOF) recommends that adults under age 50 get 400 - 800 international units (IU) of vitamin D every day, and that adults age 50 and older get 800 - 1,000 IU of vitamin D every day. For certain high risk individuals, higher dosages may be needed.
Today the Institute of Medicine (IOM) released updated recommendations regarding calcium and vitamin D intake. IOM recommends 600 international units (IU) of vitamin D every day for most healthy adults under age 71 and 800 IU for healthy people age 71 and older. The updated IOM recommendations for vitamin D intake are sufficient for most healthy adults, however, some adults may need more.
WASHINGTON, DC (October 14, 2010) — Osteoporosis is a serious, widespread and growing public health threat, according to the National Osteoporosis Foundation (NOF). NOF welcomes any new FDA approved treatment options, such as AtelviaTM, that will help patients address this prevalent disease. NOF estimates 10 million Americans have osteoporosis and another 34 million are at risk for the disease.
The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk.
To read more visit, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm
The Bone Health Challenge kicks-off on World Osteoporosis Day, October 20th, connecting women everywhere to the leading bone health resources in the nation
WASHINGTON, DC (September 28, 2010) - NOF has been approved as a provider of continuing education for nurses (CNE) by the American Nurses Credentialing Center (ANCC) for a period of two years. ANCC’s Accreditation Program specifies a comprehensive set of educational design criteria to ensure that continuing education activities are effectively planned, implemented, and evaluated according to educational standards and adult learning principles. ANCC accreditation of a continuing nursing education program is the hallmark of quality.